Asthma

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Doctors of all fields, including pulmonologists, are coming together to collaborate on research regarding the ongoing threat of the coronavirus.

Telehealth tools can identify someone whose symptoms are worsening and connect them to a medical professional.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

The label update comes after findings have repeatedly shown an associated risk of neuropsychiatric events.

The FDA announced the first approval of ProAir HFA—1 of the most popular inhalers in the US market.

A new guidance breaks ground as the first of its kind to assist physicians in screening for, and treating, vaping-associated respiratory disease syndrome.

New follow-up data shows older patients with COPD characterized by high blood eosinophil counts may benefit from the biologic.

New VDAART follow-up findings show at-risk children are not safer from asthma or recurrent wheeze when their mother takes prenatal vitamin D.

An analysis of the MESA study is shedding light on the potential association between having persistent asthma and developing atrial fibrillation.

Tiotropium reduces all-cause and asthma-related hospitalizations and emergency department visits.

New research into the role of legislation on vaping use shows certain laws may be more effective than others.

The FDA will rule on the type 2 inflammation-targeting biologic for another indication this May.

New data shows the market-controlling e-cigarette product nearly doubled its rate of young adult users in just 1 year.

New analysis feeds the belief that testosterone and estradiol influence asthma disparity between men and women.

A meta-analysis shows an association between respiratory burden and greater dementia risk, but the causes are still unknown.

A long-term comparison trial with smokers motivated to quit show the combination of alternative nicotine products could slightly and safely improve cessation.

A comparison of virtual training to in-person education showed the former was noninferior to the latter among patients with asthma or COPD.

An international, 5000-patient cohort shows a majority of patients are white, female, and non-smokers.

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

How to weigh the 5 agents from the drug class, which have each shown differing benefit in younger patients.

For what other indications, and in what regimens, are investigators assessing the drug class?

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

How the greatest use of the drug class may just come in the most severe cases.